Le Covifenz est un vaccin contre la COVID-19 de la compagnie Medicago. Il est basé sur une technologie classique, à protéines recombinantes avec adjuvant. Le CIQ recommande l’utilisation du vaccin Covifenz en série primaire pour les personnes de 18 à 64 ans ayant une contre-indication à l’administration d’un vaccin à ARNm ou qui refuseraient ce dernier type de vaccin.
Document intérimaire
Utilisé pour des documents qui seront mis à jour.
-
19 avril 2022
-
14 avril 2022
Le présent document vise à harmoniser les définitions des variants du SRAS-CoV-2 et la terminologie employée pour leur classification au Québec, au regard de celles de l’Agence de la santé publique du Canada (ASPC), des Centers for Disease Control and Prevention (CDC) américains et de l’Organisation mondiale de la Santé (OMS).
-
11 avril 2022
Le présent document vise à dresser un portrait du nombre d’enfants ayant une admission hospitalière associée au syndrome inflammatoire multisystémique de l’enfant (SIME) lié ou non à la COVID-19 dans le cadre de la vigie du SRAS-CoV-2 au Québec.
-
5 avril 2022
In the current context of childcare and school closures and the suspension of activities outside the family household, the social environment of children is changing rapidly and generates concerns about their safety. The literature also provides evidence that points to an increase risk of violence during periods of crisis. Under normal circumstances, a large proportion of children in Québec are affected by violence and maltreatment. For example, in 2018, many children experienced repeated psychological abuse and violent parental behaviour. Currently, the environments that act as safety nets to detect and report cases of violence and maltreatment toward children are inaccessible. To date, few data are available to quantify the problem in Québec since the beginning of the COVID-19...
-
28 mars 2022
The COVID-19 pandemic and the measures put in place to reduce the spread of the virus are transforming the daily lives and living environments of Quebec families. This document identifies the conditions created by the context of COVID-19 that may influence the development of children aged 0 to 5 and examines different public health measures to be put in place or adapted to support professional workers in contact with families and children. Particular attention was paid to vulnerable populations and social inequalities in health.
-
17 mars 2022
The general objective of this document is to support regional public health authorities in implementing action plans to promote mental health, community resilience and social cohesion in the context of the COVID-19 pandemic.
-
17 mars 2022
Following a request from the Ministère de la Santé et des Services sociaux, this document aims to review the knowledge and recommendations surrounding the use of screens by children and young people and to propose orientations with regard to the main messages that should be conveyed when raising public awareness about the risks associated with the overuse of screens in the context of a pandemic. Particular attention is placed on the effects of screens on young people, given that they are increasingly exposed to them in their various living environments and that they are the target of most of the existing recommendations.
-
16 mars 2022
This document presents measures and means to mitigate the effects of the pandemic on food insecurity.
-
9 février 2022
Cette analyse est destinée aux milieux de travail, aux décideurs et aux intervenants du réseau de santé publique et vise à identifier les situations de travail en-dehors des milieux de soins où l’utilisation d’un appareil de protection respiratoire (APR) de type N95 peut être considéré. Rappelons que les équipements de protection individuelle (EPI), dont font partie le masque N95 et le masque médical, sont l’une des mesures prévues à la hiérarchie des mesures de contrôle en milieu de travail de la COVID-19 (Groupe de travail SAT-COVID-19, 2021) et doivent être déployés en complément des autres mesures prévues cette hiérarchie
-
22 novembre 2021
This questionnaire aims to screen workers before entering their workplace to exclude those who are symptomatic and who have not had contact with a known case of COVID-19 already followed by public health authorities.
The questionnaire is intended to be completed by employees themselves on their workplace (other than health care facilities) to ensure the rapid removal of workers potentially infected with COVID-19 and to prevent its transmission to others in the workplace.
Employees with positive answers in their questionnaires should call 1 877 644 4545 or 811 to receive instructions (alternatively, check www.quebec.ca for local phone numbers). When calling, the person should specify that...
Pages
